Model-Based Dose Selection in Adults: Scientific Principles, Clinical Applications, and Emerging Trends

Abstract

Model-based dose selection in adults has revolutionized precision medicine by leveraging pharmacokinetic and pharmacodynamic modeling for individualized therapy. This review critically examines the scientific underpinnings, clinical relevance, and impactful outcomes of model-based approaches, integrating recent evidence and guideline-based recommendations. Emphasis is placed on mechanism-driven dosing strategies, risk factor assessment, and practical implications for optimizing efficacy and minimizing adverse effects in adult patient populations.

Introduction

Contemporary pharmacotherapy increasingly recognizes the heterogeneity of adult patient populations, necessitating precision in dose selection to balance efficacy and safety. Traditional fixed-dose strategies often fail to account for inter-individual variability in drug disposition and response. Model-based dose selection anchored in mathematical modeling of pharmacokinetics (PK) and pharmacodynamics (PD) has emerged as a scientifically rigorous approach, enabling clinicians to tailor therapy according to individual patient characteristics and disease states. This article provides a comprehensive review of the principles and clinical applications of model-based dosing, with a focus on adults, integrating current evidence and expert consensus.

Epidemiology / Disease Burden

Dose optimization is a universal concern across adult medicine, influencing outcomes in a range of conditions from infectious diseases to oncology, cardiology, and chronic illnesses. Suboptimal dosing contributes significantly to morbidity, mortality, adverse drug reactions, and healthcare costs globally. Inappropriate dosing accounts for up to 20% of medication errors in hospitalized adults, with elderly and polypharmacy patients particularly at risk. Model-based dosing has the potential to address these issues by enhancing therapeutic precision, thus reducing the burden of adverse outcomes and improving population health metrics.

Pathophysiology

Inter-individual variability in drug response is underpinned by complex pathophysiological mechanisms. Factors such as organ dysfunction (hepatic, renal), genetic polymorphisms affecting drug-metabolizing enzymes, disease states altering drug binding, and age-related physiological changes all modulate PK/PD relationships. Model-based approaches integrate these variables, using compartmental and non-compartmental analyses to predict drug concentrations over time and link them to pharmacologic effects. Mechanism-based models, including physiologically based PK (PBPK) and population PK models, enable simulation of diverse clinical scenarios, facilitating rational dose selection tailored to the pathophysiologic context of each adult patient.

Risk Factors

Numerous risk factors influence the need for individualized dosing in adults. Renal and hepatic impairment, extremes of age, obesity, genetic variants (e.g., CYP450 polymorphisms), comorbidities, and polypharmacy are predominant considerations. Model-based dosing incorporates these factors, often quantified through covariate analysis in population models, to identify patients at risk for subtherapeutic or toxic exposures. This approach is especially critical in drugs with narrow therapeutic indices or nonlinear PK, such as anticoagulants, antiepileptics, and certain chemotherapeutics.

Clinical Features

Clinical manifestations of inappropriate dosing range from lack of therapeutic effect to overt toxicity. In adults, signs may include suboptimal disease control, unexpected side effects, or organ dysfunction. Model-based dosing enables early identification of patients at risk, supporting proactive dose adjustments. For example, in antibiotics, therapeutic drug monitoring combined with PK modeling can prevent underdosing in critically ill adults, while in oncology, model-based approaches can mitigate myelosuppression risk by individualizing chemotherapy regimens.

Diagnosis

While diagnosis traditionally refers to disease identification, in the context of model-based dosing, it pertains to the assessment of factors influencing drug response. This includes laboratory evaluation of renal and hepatic function, genotyping for drug-metabolizing enzymes, assessment of drug interactions, and quantification of relevant biomarkers. Advanced modeling platforms utilize these diagnostic data to simulate individualized dosing scenarios, supporting evidence-based clinical decision-making at the point of care.

Treatment & Management

Model-based dosing is increasingly integrated into routine adult pharmacotherapy, particularly for drugs with complex PK/PD profiles. Management strategies involve the use of software platforms and Bayesian forecasting to individualize doses in real-time, based on patient-specific parameters and observed drug concentrations. Clinical implementation requires close collaboration between prescribers, pharmacists, and laboratory personnel, as well as ongoing education to interpret model outputs. Model-based dosing is now standard of care in several domains, including vancomycin therapy in adults and dosing of oral anticoagulants in atrial fibrillation.

Recent Advances / Emerging Therapies

Recent years have witnessed substantial advances in model-based dosing, driven by technological innovation and expanded clinical trial data. Integration of artificial intelligence and machine learning with PBPK and population PK models has enabled more accurate predictions of drug response across diverse populations. Adaptive clinical trials now employ model-based dose selection to optimize benefit-risk ratios efficiently. Additionally, regulatory agencies such as the FDA and EMA increasingly mandate model-based approaches in drug development and post-marketing surveillance, underscoring their clinical importance.

Guideline Recommendations

Consensus guidelines from leading bodies, including the Infectious Diseases Society of America (IDSA), American Society of Clinical Oncology (ASCO), and European Medicines Agency (EMA), advocate for model-based dose selection in specific high-risk contexts. Recommendations emphasize the integration of PK/PD modeling and therapeutic drug monitoring, especially for antimicrobials, immunosuppressants, and antineoplastic agents in adults. Guideline-directed implementation is associated with improved clinical outcomes, reduced adverse events, and more efficient use of healthcare resources.

Conclusion

Model-based dose selection represents a paradigm shift in adult pharmacotherapy, enabling clinicians to navigate the complexities of inter-individual variability with scientific precision. By incorporating mechanistic, patient-specific data into dosing decisions, this approach enhances efficacy, safety, and overall clinical outcomes. Ongoing research, technological advances, and evolving guidelines will continue to shape the future landscape of model-based dosing, reinforcing its critical role in precision medicine for adult patients.